Mode
Text Size
Log in / Sign up
N/A Completed N=168 Randomized Quadruple-blind Prevention

Effects of Lutein and Zeaxanthin Supplementation on Early Age-related Macular Degeneration

Source: ClinicalTrials.gov NCT01528605 ↗
Enrolled (actual)
168
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcomePrimary: Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years — 0.315; 0.307; 0.315; 0.320 density units — p=<0.05

Summary

This study is to investigate the protective effects of supplemental lutein and zeaxanthin on early age-related macular degeneration (AMD) patients in China.

Outcome Measures

OutcomeResultp-value
PRIMARY
Changes of Macular Pigment Optical Density (MPOD) During 48 Weeks and 2 Years
0.315; 0.307; 0.315; 0.320; 0.327; 0.300 <0.05 sig
SECONDARY
Changes of Serum Xanthophylls Concentrations During the Intervention
0.330; 0.318; 0.301; 0.244; 0.258; 0.870 <0.05 sig
SECONDARY
Changes of Best-spectacle Corrected Visual Acuity (BSCVA) During the Intervention
53.037; 54.769; 54.539; 56.840; 56.481; 55.038 >0.05
SECONDARY
Changes of Contrast Sensitivity (CSF) Measured by CSV-100 During the Intervention
— —
SECONDARY
Changes of Flash Recovery Time (FRT) Measured by MDD-2 Macular Adaptometer
— —
SECONDARY
Changes From Baseline in Multifocal Electroretinogram (mfERG) at 48 Weeks
— —
SECONDARY
Changes From Baseline in Microperimetry (MP) During the Intervention
— —
SECONDARY
Changes of Food Pattern From Baseline by Food Frequency Questionnaire During the Intervention
— —

Eligibility Criteria

Inclusion Criteria

  • aged over 50 years, Chinese of the Han nationality
  • diagnosed as age-related macular degeneration
  • did not take lutein or zeaxanthin supplements in the past half a year
  • good general health
  • corrected visual acuity above 0.25 (20/80)
  • did not take optical laser or medical treatments

Exclusion Criteria

  • had other ocular diseases, such as glaucoma, macular pucker, optic neuropathy, diabetic retinopathy etc.
  • had nervous system diseases, stroke, Type I diabetes
  • had diseases effected nutrients absorption, such as Crohn' s disease
  • had turbid ocular media or transplanted intraocular lenses
  • reported abnormal digestive condition
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01528605). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search